enGene (NASDAQ:ENGN) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $27.00 price target on the stock.
enGene Holdings Inc. (ENGN)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ENGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENGN alerts
High impacting enGene Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ENGN
News
- enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial [Yahoo! Finance]Yahoo! Finance
- enGene (NASDAQ:ENGN) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing ReadinessBusiness Wire
- enGene to Present at the Piper Sandler 37th Annual Healthcare ConferenceBusiness Wire
- enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded WarrantsBusiness Wire
ENGN
Sec Filings
- 11/18/25 - Form SCHEDULE
- 11/18/25 - Form SCHEDULE
- 11/14/25 - Form 8-K
- ENGN's page on the SEC website